Lexicon Pharmaceuticals
LXRX
121 hedge funds and large institutions have $582M invested in Lexicon Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 18 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 122 → 121 (-1)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
1.13% less ownership
Funds ownership: 99.48% → 98.34% (-1.1%)
17% less capital invested
Capital invested by funds: $700M → $582M (-$118M)
74% less call options, than puts
Call options by funds: $1.36M | Put options by funds: $5.14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$16.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.68M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$2.73M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$2.05M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$11.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.56M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.38M |
| 4 |
SGA
Sector Gamma AS
Oslo,
Norway
|
-$2.95M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.19M |
LXRX Hedge Fund Activity: Q1 2019 in Review
121 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2019, worth a combined $582M — down 17% from $700M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of LXRX and 17 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 39 added.
The largest buyer was First Manhattan, opening a new position worth an estimated $16.7M. The largest seller was UBS AM, cutting an estimated $11.1M.
- 121 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2019, down from 122 in Q4 2018.
- Funds reported $582M of Lexicon Pharmaceuticals stock for Q1 2019, down 17% quarter-over-quarter.
- 17 funds opened new Lexicon Pharmaceuticals positions in Q1 2019 and 18 closed out, a net change of -1 holder.
- The largest Lexicon Pharmaceuticals buyer in Q1 2019 was First Manhattan, an estimated $16.7M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2019 was UBS AM, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2019.